Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
18 years or older with diagnosis of asthma for at least 6 months
Clinically stable asthma at the time of study enrollment
Clinical requirements for treatment with ICS as outlined in the Canadian Asthma Consensus Guidelines
If patients are currently on ICS, the dose must be stable for 3 months and they must be willing to switch
You may not be if
On combination therapy (ICS + long acting beta-2-agonist) for asthma in the past 3 months or require combination therapy
Severe asthma, one or more asthma exacerbations in the last 3 months requiring hospitalization or emergency room visit, or patients who have used systemic steroids more than 3 times in the past 6 months or who are currently using systemic steroids
Mild asthma requiring short acting beta-2-agonists only
Patients with a contraindication to ICS therapy
Any other disease or medical condition requiring further clinical evaluation, which in the opinion of the Primary Care Practitioner may interfere with the clinical study or interfere with the diagnosis of asthma.
Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women
Clareo Health | Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
